India’s Strides Said Pondering Sale Of Profitable Agila Injectables Unit
This article was originally published in PharmAsia News
Executive Summary
India’s Strides Arcolab reportedly is considering sale of its unit that makes injectable medicines, Agila Specialties, considered by some to be worth more than $800 million.